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Abstract
Background: Leukotrienes (LTs) belong to the large family of lipid mediators implicated in various inflammatory
conditions such as asthma and rheumatoid arthritis. Four distinct types (BLT1, BLT2, CysLT1 and CysLT2) of G-
protein-coupled receptors for LTs have been identified. Several studies have reported that LTs are involved in
inflammatory pain, but the mechanism and the expression of LT receptors in the nociceptive pathway are
unknown.
Results: We investigated the precise expression of these four types of LT receptors in the adult rat dorsal root
ganglion (DRG) using reverse transcription-polymerase reaction (RT-PCR) and radioisotope-labeled in situ
hybridization histochemistry (ISHH). We detected mRNAs for BLT1 and CysLT2 in the DRG, but not for BLT2 and
CysLT1. CysLT2 mRNA was preferentially expressed by small sized DRG neurons (about 36% of total neurons),
whereas BLT1 mRNA was expressed by non-neuronal cells. Double labeling analysis of CysLT2 with NF-200,
calcitonin gene-related peptide (CGRP), isolectin B4 (IB4), transient receptor potential vanilloid subfamily 1 (TRPV1)
and P2X3 receptor revealed that many CysLT2-labeled neurons were localized with unmyelinated and non-
peptidergic neurons, and interestingly, CysLT2 mRNA heavily co-localized with TRPV1 and P2X3-positive neurons.
Intraplantar injection of LTC4, a CysLT2 receptor agonist, itself did not induce the thermal hyperalgesia,
spontaneous pain behaviors or swelling of hind paw. However, pretreatment of LTC4 remarkably enhanced the
painful behaviors produced by alpha, beta-methylene adenosine 5’-triphosphate (ab-me-ATP), a P2X3 receptor
agonist.
Conclusions: These data suggests that CysLT2 expressed in DRG neurons may play a role as a modulator of P2X3,
and contribute to a potentiation of the neuronal activity following peripheral inflammation.
Background
The leukotrienes (LTs) are a family of biologically active
lipid mediators. They are synthesized from arachidonic
acid (AA) via the 5-lipoxygenase pathway. AA is enzy-
matically converted to LTB4, LTC4, LTD4 and LTE4
that are known as bioactive LTs. LTC4, LTD4 and
LTE4 are collectively termed the cysteinyl leukotrienes
(CysLTs). LTs are peripherally produced by activated
leukocytes in response to peripheral inflammation, such
as asthma and atopic dermatitis [1,2]. Four different
types (BLT1, BLT2, CysLT1 and CysLT2) of G-protein-
coupled receptor for LT have been cloned [3-6]. LTB4
activates BLT1 and BLT2, and CysLTs activate CysLT1
and CysLT2.
Peripheral inflammation often elicits mechanical and
thermal hyperalgesia. The most studied of these lipid
mediators are the prostaglandins (PGs) of the cyclooxy-
genase pathway of AA metabolism [7,8]. Expression of
G-protein-coupled receptors of EP for E-type PG is
localized in C-fibers, unmyelinated nociceptive fibers, in
the dorsal root ganglion (DRG) [8]. Activation of EP sig-
naling plays a role in neuronal sensitization mediating
modulation of the transient receptor potential vanilloid
subfamily 1 (TRPV1) receptor and P2X3 receptor [9,10].
Intradermal injection of LTB4 has been shown to pro-
duce both thermal and mechanical hyperalgesia [11,12].
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matory pain induced by carrageenan [13]. Furthermore,
we demonstrated that an increase in LT synthesis in
microglia in the spinal cord induced by peripheral nerve
injury contributes to neuropathic pain [14]. However, in
the periphery, the mechanism of the nociception
induced by LTs is unknown and the precise expression
pattern of LT receptors in the DRG has not been clari-
fied. The purpose of this study is to examine the expres-
sion of LT receptor mRNAs in the DRG to assess
whether LT receptors are expressed in nociceptive neu-
rons. Furthermore, we attempted to determine the noci-
ceptive role of LT receptors in DRG by behavioral
analyses.
Results
Expression of LT receptors in the DRG
To examine whether sensory neurons express the LT
receptor mRNAs, we performed reverse transcription-
polymerase chain reaction (RT-PCR) and in situ hybridiza-
tion histochemistry (ISHH) using adult rat DRG. The
mRNAs for BLT1 and CysLT2 mRNAs were expressed in
the DRG, but not the BLT2 and CysLT1 mRNAs (Figure
1A). For the ISHH, the BLT1 mRNA was expressed in an
extremely limited population of non-neuronal cells (Figure
1B, C). With brightfield imaging of ISHH for the BLT1
mRNA, silver grains were accumulated over the non-neu-
ronal cells whose nuclei were heavily stained with hema-
toxylin (Figure 1C). In contrast to the BLT1 mRNA, a
subpopulation of DRG neurons expressed CysLT2 mRNA
(Figure 1D, E). The darkfield photograph displayed distin-
guishable clusters of silver grains over the tissue with
minimal background signals (Figure 1D). The brightfield
and high magnification images confirmed the presence of
CysLT2 on neuronal cell bodies (Figure 1E). To evaluate
objectively the expression of the CysLT2 mRNA in DRG
neurons, we measured, calculated, and plotted the signal-
to-noise (S/N) ratio and cross-sectional area of each
Figure 1 Expression of LT receptor mRNAs in the rat DRG. (A) The expression of mRNAs for LT receptors were determined by the RT-PCR
technique. Gel panel shows PCR products from the L4, 5 DRGs taken from naive rats. (B, D) Low-magnification darkfield images of ISHH show
BLT1 and CysLT2 mRNAs of naive rats, respectively. (C, E) Higher-magnification brightfield images of the left-hand images. Arrows indicate
positively labeled cells by ISHH. Scale bars: B, D; 500 μm, E; 25 μm, C; 12.5 μm.
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profiles with a grain density of 20-fold the background
level or higher (S/N ratio > 20) were considered positively
labeled for this mRNA. With this criterion, 35.8 ± 3.3% of
profiles were positively labeled for CysLT2 mRNA of the
total DRG neurons (Table 1). The scattergram revealed
that CysLT2 mRNA was expressed more intensely by the
neurons with cell profiles less than 600 μm
2 compared
with the medium or large-size neurons. The size distribu-
tion of the positively labeled profiles for CysLT2 mRNA is
shown in Table 1. The CysLT2 mRNA was expressed in a
limited population of small (< 600 μm
2) and medium-size
(600-1200 μm
2) neurons, whereas large-size (> 1200 μm
2)
neurons were not labeled for this mRNA (Table 1). The
neuronal size definition was described previously [15].
Characterization of CysLT2-labeled neurons
To characterize the expression of CysLT2 mRNA in DRG
neurons, we used double labeling ISHH with immunohis-
tochemistry (IHC) for NF-200, a maker of myelinated A-
fiber neurons. We found NF-200-immunoreactive neu-
rons in 36.3 ± 1.5% of the total neurons (Table 2). No
specific staining was observed in the absence of the pri-
mary antibody (data not shown). The results of double
labeling analysis of CysLT2 mRNA with NF-200 showed
that 9.6 ± 3.4% of the CysLT2 mRNA-positive profiles
expressed NF-200, conversely, 8.0 ± 2.3% of NF-200-pro-
files expressed CysLT2 mRNA (Figure 3A; Table 2). The
CysLT2 mRNA was expressed in 44.0% of NF-200 nega-
tive profiles, which were considered unmyelinated neu-
rons (C-fiber). We tested the co-expression of CysLT2
mRNA with CGRP and IB4 in order to identify the pep-
tide-dependent neuronal subpopulations [16], using
double labeling of ISHH with IHC. We observed CGRP-
immunoreactive and IB4-binding neurons in 39.0 ± 3.1%
and 37.5 ± 2.9% of the total neuronal profiles, respec-
tively (Table 2). The results of the double labeling analy-
sis of CysLT2 mRNA with CGRP and IB4 showed that
27.5% of the CysLT2 mRNA-positive profiles expressed
CGRP; conversely, 25.6% of CGRP-profiles expressed
CysLT2 mRNA (Figure 3B, Table 2), and 85.6% of the
CysLT2 mRNA-positive profiles expressed IB4, conver-
sely, 82.0% of IB4-profiles expressed CysLT2 mRNA (Fig-
ure 3C, Table 2). These results indicated that CysLT2
mRNA was expressed in non-peptidergic neurons rather
than peptidergic neurons.
N e x t ,t oe x a m i n ew h e t h e rC y s L T 2m R N Aw a sc o -
expressed with TRPV1 and P2X3 that are considered as
pivotal nociceptors in primary afferent fibers, we tested
the percentage of colocalization of CysLT2 mRNA with
TRPV1 and P2X3. We observed TRPV1 and P2X3-ir
neurons in 36.7 ± 1.5% and 34.0 ± 1.9% of the total neu-
ronal profiles, respectively (Table 2). Further, 71.2% of
the CysLT2 mRNA-positive profiles expressed TRPV1;
conversely, 69.6% TRPV1- positive profiles expressed
CysLT2 mRNA (Figure 3D; Table 2) and 80.7% of the
CysLT2 mRNA-positive profiles expressed P2X3; con-
versely, 88.8% P2X3- positive profiles expressed CysLT2
mRNA (Figure 3E; Table 3).
Effect of LTC4, a CysLT2 receptor agonist, on pain-related
behaviors
Leukotrienes are known as proinflammatory lipid med-
iators, and CysLT2 was co-localized with TRPV1, a heat
Figure 2 Scatterplot diagram of the DRG neurons expressed
mRNA for CysLT2. Individual cell profiles are plotted according to
the cross-sectional area and signal intensity (n = 4, 2819 cells). The
dashed line indicates the borderline between the negatively and
positively labeled neurons (S/N ratio = 20).
Table 1 Distribution of CysLT2 mRNA Expression in the
DRG
Small Medium Large
(< 600 μm
2) (600-1200 μm
2) (> 1200 μm
2)
CysLT2 76.5 ± 6.5 23.5 ± 6.5 0.0 ± 0.0
Percentages of CysLT2 mRNA-expressing cells in total positive cells.
Mean ± SEM (n = 4).
Table 2 Percentages of Colocalization of CysLT2 mRNA
with NF-200, CGRP, IB4, TRPV1 and P2X3
Immunoreactive Neurons in DRG
y x/y y/x
NF-200 (36.3%) 8.0 ± 2.3 9.6 ± 3.4
CGRP (39.0%) 25.6 ± 3.0 27.5 ± 3.9
IB4 (37.5%) 82.0 ± 4.6 85.6 ± 1.5
TRPV1 (36.7%) 69.6 ± 4.6 71.2 ± 1.8
P2X3 (34.0%) 88.8 ± 2.2 80.7 ± 3.7
x/y means the percentage of CysLT2 (x) mRNA-expressing cells in y
immunoreactive cells. (number); means percentage of the neurons expressing
the corresponding immunoreactivity in total DRG neurons. Mean ± SEM (n =
4).
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CysLT2 receptor agonist, leads to thermal hyperalgesia
(Figure 4A). We tested heat sensitivity of the hind paw
after intraplantar injection of LTC4 (8 fmol, 0.8 pmol
and 80 pmol). None of doses affected on heat sensitivity
at 10, 30 and 60 min after LTC4 injection (Figure 4A).
LTC4 alone (0.8 pmol) did not contribute to the noci-
fensive behaviors (pain-like behaviors) and swelling of
the hind paw (data not shown).
Next, because CysLT2-positive cells heavily co-loca-
lized with P2X3, we examined whether intraplantar
injection of LTC4 can enhance the nocifensive beha-
viors induced by alpha, beta-methylene adenosine 5’-
triphosphate (ab-me-ATP), a P2X3 receptor agonist.
In normal rats, ab-me-ATP (100 μmol) consistently
induced periods of intermittent hind paw-lifting beha-
vior, which mostly began within 30-40 s after the
injection and continued for the first 4 min [17]. Intra-
plantar injection of LTC4 at 0.8 pmol before the ab-
me-ATP injection induced a remarkable increase of
paw-lifting behaviors (Figure 4B). The increase of
duration of paw lifting was significantly larger than
that after the injection of PBS plus ab-me-ATP (Figure
4B). Lower and higher doses of LTC4 (< 80 fmol and 8
pmol <) did not show the alteration of nocifensive
behaviors by ab-me-ATP injection (Figure 4B). Poten-
tiation of nocifensive behaviors induced by LTC4
showed a bell-shaped concentration-effect curve, with
no significant effect at lower and higher amounts.
Pretreatment with the LTC4 increased ab-me-ATP-
induced Fos expression
A single injection of ab-me-ATP (100 nmol) induced
F o se x p r e s s i o ni nas m a l ln u m b e ro fs p i n a ln e u r o n s
(Figure 4C). The labeled neurons were in the superficial
dorsal horn but were relatively distributed throughout
the spinal cord laminae. The injection of ab-me-ATP
(100 nmol) into the hind paw of the LTC4 (0.8 pmol)-
pretreated rats induced elevated Fos expression in spinal
neurons (Figure 4D). The Fos-labeled cells were promi-
nently observed in the medial half of the superficial
laminae of the spinal dorsal horn. The number of Fos-
labeled cells in laminae I-II induced by the injection of
ab-me-ATP (100 nmol) in rats pretreated LTC4 (0.8
Figure 3 Distribution of CysLT2 mRNA in histochemically identified neuronal subpopulations in the rat DRG. Brightfield images of
combined immunohistochemistry for (A) NF-200, (B) CGRP, (C) IB4, (D) TRPV1, (E) P2X3 with ISHH for CysLT2 mRNA. Arrows indicate examples of
double-labeled cells. Solid arrowheads indicate positively labeled cells by ISHH and open arrowheads indicate examples of immunoreactive cells.
Scale bars; 25 μm.
Table 3 Sequence Location of Primers Used in This Study
Primer
Gene GenBank Accession no. Forward Reverse
BLT1 AB025230 1812-1831 2231-2212
BLT2 AB052660 488-507 939-920
CysLT1 AB052685 234-253 698-679
CysLT2 AB052661 105-124 670-651
GAPDH M17701 80-99 350-331
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those pretreated with PBS (Figure 4E).
Discussion
LTs are lipid mediators with a proinflammatory profile
and have been implicated in the pathogenesis of several
types of inflammation [1]. For example, the blood and
synovial fluids of patients with rheumatoid arthritis con-
tain higher levels of LTB4 than people without rheuma-
toid arthritis [18]. LTB4 is known as a potent neutrophil
chemotactic agent. It is considered that the neutrophils
that are infiltrated by rheumatoid arthritis produce
LTB4 in synovial fluids and induce the inflammatory
condition. Several studies have demonstrated that LTs
are involved in inflammatory pain [11-13]. It is well
known that nerve growth factor (NGF) is up-regulated
in inflammatory tissue and sensitizes nociceptors [19]
leading to thermal hyperalgesia [20]. It has reported that
NGF increased LTB4 in the rat paw skin and these
results suggested the participation of LTB4 in NGF-
induced local thermal hyperalgesia [21]. Furthermore,
Trang et al. have reported that intrathecal administra-
tion of LTB4 leads to thermal hyperalgesia, and a BLT1
receptor antagonist suppresses this hyperalgesia [22].
These previous reports indicate that LTs in peripheral
tissues may have an effect on primary afferents.
In the present study, we demonstrated the expression
of LT receptors, BLT1, BLT2, CysLT1, and CysLT2, in
the adult rat DRG. We could not detect BLT2 and
CysLT1 mRNAs in the DRG. We found the BLT1
mRNA expression in non-neuronal cells, but Andoh et
al. reported expression of BLT1 in mouse DRG neurons
[23]. This discrepancy may be due to the difference of
the species (rat versus mouse) or the methods (ISHH
Figure 4 Effect of LTC4, a CysLT2 receptor agonist, on ab-me-ATP induced pain behaviors and Fos expression. (A) Thermal sensitivity
was evaluated by measuring withdrawal latency (sec) at pre (pretreatment), 10, 30 and 60 min after intraplantar injection of LTC4 using a plantar
test. (B) The nocifensive behaviors induced by ab-me-ATP (100 nmol) were evaluated by measuring paw-lifting duration (sec). LTC4 was given at
several doses of 8 fmol - 80 pmol/paw, and the ensuing hind paw-lifting duration over the following 4 min was measured. #p < 0.05 compared
with vehicle treated group. n = 4-6 for each group. (C, D) Fos protein immunoreactivity in the L5 spinal cord induced by ab-me-ATP (100 nmol)
alone (C) and LTC4 (0.8 pmol) followed by ab-me-ATP intraplantar injection (D). (E) Number of Fos-labeled neurons in spinal laminae I-II shown
in C and D. #p < 0.05 compared with vehicle treated group. n = 3 for each group. Scale bar: 100 μm.
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mRNA, CysLT2 mRNA was expressed in DRG neurons.
CysLT2 was cloned in 2000 [5], however, there has been
limited information of its tissue distribution in nervous
system, such as in the astrocyte in brain [24]. CysLT2 is
involved in apoptosis induced by oxygen-glucose depri-
vation in vitro [24], but its functional role remains lar-
gely unknown. We precisely quantified CysLT2 mRNA
in the adult rat DRG showing that about 40% of DRG
neurons expressed CysLT2 mRNA (S/N > 20) and small
sized DRG neurons preferentially expressed CysLT2.
Double-labeling analysis with NF-200 and CysLT2
showed that most CysLT2-labeled cells did not express
NF-200. Moreover, a lot of CysLT2-positive profiles
exclusively co-localized with IB4-binding, a quarter of
CGRP-positive neurons expressed CysLT2 mRNA.
These results indicate that CysLT2 was mainly
expressed in unmyelinated and non-peptidergic neurons.
Interestingly, CysLT2 mRNA expressing neurons were
heavily co-localized with TRPV1- or P2X3-positive neu-
rons. TRPV1, one of the TRPV family, has been cloned
and is a thermosensitive channel with a threshold of 42
degrees Celsius [25]. TRPV1 is expressed in small sized
neurons [26] and is modulated by various G-protein
coupled receptors, such as EP4 [8], protease-activated
receptor 2 [27] and neurokinin-1 receptor [28]via the
protein kinase C (PKC) pathway. 12-(S)-HPETE, a pro-
duct of 12-lipoxygenase, potentiates the TRPV1 current
in HEK cells [29]. Thompson et al. have reported that
the signaling pathway for CysLT2 is involved in the acti-
vation of PKC pathway via Gq-proteins [30]. Because it
is possible that CysLT2 can sensitize TRPV1 in primary
sensory neurons, we examined whether intraplantar
injection of LTC4 leads to thermal hyperalgesia. All
doses of LTC4 (8 fmol, 0.8 pmol and 80 pmol) did not
affect on heat sensitivity at 10, 30 and 60 min after the
injection in normal rats. The data indicate LTC4 does
not have a role on thermal hyperalgesia in a normal
condition. However, a further study is required to know
the role of LTC4 on thermal sensitivity in tissue
inflammation.
P2X3 is a ligand-gated ion channel for ATP, and
belongs to P2X family. P2X3 is of particular interest in
the context of pain pathways, because it is selectively
expressed at high levels by nociceptors [31], and electro-
physiological studies suggest that the P2X receptors in
sensory neurons may play an important role in the gen-
eration and/or modulation of the pain signaling from
the periphery to the spinal cord [32]. Furthermore, we
previously reported that P2X3 in peripheral afferents
plays a role in the induction of the hypersensitivity to
mechanical stimulation observed during peripheral
inflammation [33] and many P2X3s are co-expressed
with protease-activated receptor 2 in the rat dorsal root
ganglion neurons. Nocifensive behaviors induced by ab-
me-ATP injection to the hind paw were significantly
augmented after the application of protease-activated
receptor 2 agonists [17]. Fos expression induced by the
ab- m e - A T Pi n j e c t i o ni nd o r s a lh o r nn e u r o n sw a sa l s o
increased after the pre-application of protease-activated
receptor 2 agonists [34]. These previous studies led us
to behavioral experiments to study whether the LTC4
have a role in potentiation of pain sensation induced by
ab-me-ATP. Intraplantar injection of LTC4 before the
ab-me-ATP injection induced a significant increase of
paw-lifting behaviors and Fos expression in the spinal
dorsal horn. Based on the finding described in the pre-
sent study, we concluded that CysLT2, the receptor of
LTC4, located in the primary afferent, might modulate
the activation of P2X3 by the injection of ab-me-ATP.
Conclusions
We found that the CysLT2 is preferentially expressed by
small-sized, non-peptidergic and nociceptive neurons
expressing TRPV1 or P2X3 in the DRG, and contribute
to the potentiation of pain behaviors induced by ab-me-
ATP. Our current observations in the context of pre-
vious findings may indicate a novel functional role of
CysLT2 in the peripheral nervous system.
Methods
Experimental animals
Male Sprague-Dawley rats weighing 200-250 g were
used as subjects. All animal experimental procedures
were approved by the Hyogo College of Medicine Com-
mittee on Animal Research and were performed in
accordance with the National Institutes of Health guide-
lines on animal care. Rats were used for the behavioral
analyses. A few minutes after unilateral intraplantar
injection of leukotriene C4 (LTC4, Cayman chemical,
Ann Arbor, MI) [5S-hydroxy-6R-(S-glutathionyl)-
7E,9E,11Z,14Z-eicosatetraenoic acid] [0.8 pmol-8 nmol
in 50 μl of phosphate-buffered saline (PBS)], an agonist
of CysLT2 receptor, the rats received intradermal injec-
tion of ab-me-ATP (100 nmol, Sigma, St Louis, Mis-
souri, USA) in 50 μl PBS to the plantar surface of the
left hind paw. The rats were placed in a wire mesh cage
immediately after the injection, and the duration of hind
paw lifting during the first 4 min were measured
[17,35]. For measurement of thermal hyperalgesia, the
withdrawal latency (sec) of hind paw was measured
from 10 to 60 min after intraplantar injection of LTC4.
Thermal hyperalgesia was assessed with a plantar test
(7370, Ugo Basile, Comerio, Italy). The detailed method
of thermal sensitivity measurement in rat hind paw was
described previously [36].
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and in situ hybridization histochemistry (ISHH)
The rats were killed by decapitation under deep ether
anesthesia. L4 and L5 DRGs were removed and rapidly
frozen with powdered dry ice and stored at 80°C until
use. Extraction of total RNA was done by the single step
extraction method using ISOGEN (Nippon Gene,
Tokyo, Japan) that was described in a previous paper
[37]. The forward and reverse primers specific for rat
BLT1, BLT2, CysLT1, CysLT2 and GAPDH were
d e s i g n e da ss h o w ni nT a b l e3 .A m p l i f i c a t i o nc y c l ew e r e
33 for each cDNA. The amplified cDNA was cloned
into p-GEM T-easy (Promega, MI, USA) and sequenced.
These clones were used to generate the cRNA probes
for ISHH.
For ISHH, the rats were killed by decapitation under
deep ether anesthesia. The bilateral L4 and L5 DRGs
were dissected out, rapidly frozen in powdered dry ice,
and cut on a cryostat at 5 μm thickness. The protocol
for ISHH was base on a publish method [38]. Using the
enzyme-digested cloned, a
35S UTP-labeled antisense
and sense cRNA probe were synthesized. Thea
35S-
labeled probes in hybridization buffer were placed on
the section, and then incubated at 55°C overnight. Sec-
tions were then washed and treated with 1 μg/ml RNase
A. Subsequently, sections were dehydrated and air-dried.
After the hybridization reaction, the slides were coated
with NTB emulsion (Kodak, Rochester, NY, USA) and
exposed for 3-4 weeks. Once developed in D-19
(Kodak), the sections were stained with hematoxylin-
eosin and coverslipped.
Double labeling analysis of ISHH with
immunohistochemistry (IHC)
For double labeling of ISHH with IHC, the rats were
deeply anesthetized with sodium pentobarbital (70-80
mg ⁄ kg body weight, i.p.) and perfused transcardially
with 100 ml of 1% paraformaldehyde in 0.1 M phos-
phate buffer, pH 7.4, followed by 500 ml of 4% parafor-
maldehyde in 0.1 M phosphate buffer. The L4 and L5
DRGs were dissected out and post-fixed in the same
fixative for 4 h at 4°C, followed by immersion in 30%
sucrose in 0.1 M phosphate buffer at 4°C overnight. The
tissue was frozen in powdered dry ice and cut on a
cryostat at 5 μm thickness. The sections were processed
for IHC using the ABC method [39]. Following antibo-
dies and binding protein were used: Mouse anti-NF200
monoclonal antiserum (1:40000, Sigma, St. Louis, MO,
USA), rabbit anti-CGRP (1:10000, Amersham, Buckin-
ghamshire, UK), isolectin B4 from Griffonia simplicifolia
(IB4, 1:200, Sigma, St. Louis, MO, USA), rabbit anti-
TRPV1 (1:100, Oncogene, Cambridge, MA, USA) and
rabbit ant-P2X3 (1:500, Oncogene, Cambridge, MA,
USA). The sections were washed in TBS and then
incubated in biotinylated anti-rabbit or anti-mouse IgG
(1:400; Vector Laboratories, Burlingame, CA, USA) in
Tris buffer saline (TBS; Tris-HCl 0.1 M, NaCl 0.15 M)
containing 5% serum for 2 h at 4°C, followed by incuba-
tion in avidin-biotin-peroxidase complex (Elite ABC kit;
Vector, CA, USA) for 1 h at room temperature. The
horseradish peroxidase reaction was developed in TBS,
pH 7.4, containing 0.05% 3,39-diaminobenzidine tetrahy-
drochloride (Wako, Tokyo, Japan) and 0.01% hydrogen
peroxidase. Sections were then washed in TBS and used
for ISHH.
Immunohistochemistry for Fos expression
For Fos protein immunohistochemistry, rats were
divided into two experimental groups; group 1: rats
received injection of ab-me-ATP and PBS, and were
perfused 2 h after the injection; group 2: rats received
injection of ab-me-ATP and LTC4 (80 pmol) and were
perfused 2 h after the injection. After appropriate survi-
val times, the rats were deeply anesthetized and perfused
transcardially with 4% paraformaldehyde described in
double labeling method. L4/L5 segments of the spinal
cord were removed for immunohistochemistry as
described previously [40]. Rabbit primary antibody for
Fos (1:20000; Ab-5; Oncogene) was used. The number
of Fos-labeled neurons in laminas I-II was counted in
randomly selected sections (ten out of 18-28 sections
per rat). A labeled nucleus was judged as positively
labeled only when a structure of appropriate size and
shape indicated a clear increase in immunoreactivity
above the background, but without considering intensity
of the staining.
Quantitative analysis
Measurements of the density of silver grains over ran-
domly selected tissue profiles were performed using a
computerized image analysis system (NIH Image, ver-
sion 1.61), where only neuronal profiles that contained
nuclei were used for quantification. At a magnification
of 200× and with bright-field illumination, upper and
lower thresholds of gray level density were set such that
only silver grains were accurately discriminated from the
background in the outlined cell or tissue profile and
read by the computer pixel-by-pixel. Subsequently, the
area of discriminated pixels was measured and divided
by the area of the outlined profile, giving a grain density
for each cell or tissue profile. To reduce the risk of
biased sampling of the data because of varying emulsion
thickness, we used a signal-to-noise (S/N) ratio for each
cell in each tissue. The S/N ratio of an individual neu-
ron and its cross-sectioned area, which was computed
from the outlined profile, was plotted. Based on this
scatter gram, neurons with a grain density of ten-fold
the background level or higher (20 < S/N ratio) were
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Because a stereological approach was not used in this
study, quantification of the data may represent a biased
estimate of the actual numbers of neurons. At least 500
neurons from the L4/5 DRG of each rat were measured.
The number of positively labeled DRG neurons was
divided by the number of neuronal profiles counted in
each DRG. For IHC, only the signals that were clearly
discriminative immunoreactive profiles were considered
as the positive expressions.
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